We are live on ! Find out more
AVEO

AVEO Pharmaceuticals

Delisted

AVEO was delisted on the 19th of January, 2023.

90 hedge funds and large institutions have $173M invested in AVEO Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 24 increasing their positions, 23 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

628% more call options, than puts

Call options by funds: $10.5M | Put options by funds: $1.44M

50% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 12

7% more funds holding

Funds holding: 84 → 90 (+6)

4% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 23

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

1.52% less ownership

Funds ownership: 51.82% → 50.31% (-1.5%)

20% less capital inflows, than outflows

Capital inflows: $14.5M | Capital outflows: $18.2M

Holders
90
Holders Change
+6
Holders Change %
+7.14%
% of All Funds
2.06%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
18
Increased
24
Reduced
23
Closed
12
Calls
$10.5​M
Puts
$1.44​M
Net Calls
+$9.04​M
Net Calls Change
+$4.46​M

AVEO Hedge Fund Activity: Q1 2018 in Review

90 of the 4,376 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals (AVEO) for Q1 2018, worth a combined $173M — up 1.3% from $171M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new AVEO positions and 12 closed out — a net gain of 6 holders — while 24 added to existing stakes and 23 trimmed.

The largest buyer was Millennium Management, adding an estimated $4.18M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $3.63M sold.

  • 90 institutional investors held AVEO Pharmaceuticals (AVEO) as of Q1 2018, up from 84 in Q4 2017.
  • Funds reported $173M of AVEO Pharmaceuticals stock for Q1 2018, up 1.3% quarter-over-quarter.
  • 18 funds opened new AVEO Pharmaceuticals positions in Q1 2018 and 12 closed out, a net change of +6 holders.
  • The largest AVEO Pharmaceuticals buyer in Q1 2018 was Millennium Management, an estimated $4.18M added.
  • The largest AVEO Pharmaceuticals seller in Q1 2018 was Sphera Funds Management, an estimated $3.63M sold.

Based on aggregated 13F filings for Q1 2018.